Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.

HB 5077 (2023-2024)

https://ontology.bommaritollc.com/id/01a0d568-b367-771c-8ecf-163e7132ad2f

adms:identifier	mi-legislature-measure 2023-2024/HB/5077
dcterms:temporal	Michigan Legislature, 2023-2024 session
enacted as	2024 PA 231
primary sponsor	Curtis S VanderWall
prov:wasDerivedFrom	evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2023-HB-5077 evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2023-HB-5077 evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2023-HB-5077 evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2023-HB-5077
schema:legislationChanges	MCL 15.677 MCL 15.673
schema:legislationIdentifier	HB 5077
schema:legislationJurisdiction	Michigan
schema:legislationType	bill
schema:name	Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106.en
schema:sponsor	Regina Weiss Erin Byrnes Noah Arbit Joey Andrews Carrie Rheingans Jennifer Conlin Ann M. Bollin Sharon MacDonell Jasper Martus Julie Brixie Kara Hope Emily Dievendorf John Fitzgerald Curtis S VanderWall Betsy Coffia David Prestin Abraham Aiyash Lori Stone Felicia Brabec Christine Morse Jim Haadsma Rachel Hood Jenn Hill
schema:url	https://www.legislature.mi.gov/Bills/Bill?ObjectName=2023-HB-5077
skos:prefLabel	HB 5077 (2023-2024)en
status	public act
status date	2024-12-31xsd:date